A medicine can be essential to millions of people and still be manufactured thousands of kilometres away from those who need it.
For many African countries, that dependence has become a major economic and public health challenge. Medicines, vaccines and other medical products often travel through international supply chains before reaching hospitals, pharmacies and patients across the continent.
When those supply chains experience disruptions, the consequences can extend beyond higher business costs. Patients may face shortages, healthcare providers may struggle to maintain treatment and governments may have fewer options for responding to emergencies.
This is why African pharmaceutical manufacturing is becoming an important part of the continent’s industrial development agenda.
The African Union has set a target for at least 60% of Africa’s health product needs to be met through local manufacturing by 2040. In February 2026, African leaders reaffirmed this ambition through a presidential declaration supporting local production, coordinated procurement, investment and technology transfer.
For African pharmaceutical companies, the opportunity is significant. However, turning the policy ambition into commercially sustainable production will require more than building new factories.
African Pharmaceutical Manufacturing Has a Large Import Gap to Address
Africa remains heavily dependent on imported pharmaceutical products.
The United Nations Economic Commission for Africa’s Economic Report on Africa 2025 estimated that the continent imports approximately 70% to 90% of its pharmaceutical products, representing about $14.5 billion.
The figures demonstrate how much of Africa’s demand for medicines is currently served by producers outside the continent.
For local manufacturers, this represents potential demand that could be served domestically or regionally where production is technically feasible and commercially competitive.
However, replacing imports is not as simple as manufacturing any medicine locally.
Companies must consider production costs, product quality, regulatory requirements, reliable supplies of ingredients and whether customers can afford the finished products.
The future of African pharmaceutical manufacturing will depend on companies that can meet those requirements consistently.
African Pharmaceutical Companies Need Commercially Sustainable Production
Manufacturing medicines is expensive.
Facilities require specialised equipment, quality-control systems, trained personnel and carefully managed production environments.
Businesses also need sufficient demand to justify their investments.
A factory that operates far below capacity may struggle to compete with established international manufacturers.
This creates an important challenge for African pharmaceutical companies.
Production plans should be based on realistic market demand, not simply the availability of investment or government incentives.
Companies need to understand which medicines are regularly purchased, how procurement decisions are made and what production volumes are necessary for commercial viability.
The goal should be to build manufacturers capable of operating sustainably over time.
Local Manufacturing Can Strengthen Medicine Supply Security
The COVID-19 pandemic demonstrated the risks associated with relying heavily on international suppliers during global emergencies.
When countries faced simultaneous demand for vaccines and medical products, access became difficult for regions without substantial manufacturing capacity.
Africa CDC has repeatedly identified this experience as a major reason for expanding local production.
Local manufacturing cannot eliminate every supply-chain risk.
Factories may still depend on imported ingredients, equipment and specialised materials.
However, stronger regional production can provide additional supply options and reduce exposure to certain international disruptions.
For African pharmaceutical manufacturing, supply security is therefore both a public health objective and a potential commercial advantage.
Don’t Miss This:
Africa’s pharmaceutical opportunity extends beyond producing more medicines. The companies that develop reliable quality systems, secure consistent demand and strengthen regional distribution will be better positioned to build sustainable manufacturing businesses.
African Pharmaceutical Companies Must Reduce Dependence on Imported Ingredients
A medicine manufactured in Africa may still depend heavily on ingredients sourced from other continents.
Africa CDC’s 2025 annual report, published in 2026, found that more than 95% of active pharmaceutical ingredients used by African manufacturers are imported.
Active pharmaceutical ingredients are the substances responsible for a medicine’s intended therapeutic effect.
This dependence creates exposure to foreign exchange movements, shipping disruptions and changes in international supplier conditions.
Developing local ingredient production could strengthen the value chain, although the investment requirements are substantial.
Not every manufacturer will be able to produce its own ingredients.
Instead, African pharmaceutical companies can explore reliable sourcing arrangements, regional supplier partnerships and opportunities for specialised upstream manufacturing.
The broader objective is to create a more resilient pharmaceutical production ecosystem.
Technology Transfer Can Help African Manufacturers Build Expertise
Modern pharmaceutical production requires specialised knowledge.
Companies need expertise in formulation, manufacturing processes, quality assurance, regulatory documentation and product development.
Technology-transfer partnerships can help manufacturers acquire some of these capabilities.
Such arrangements may involve production knowledge, technical training, manufacturing processes and support for meeting regulatory requirements.
However, technology transfer should be structured to build lasting local capability.
A company that depends indefinitely on external partners for every important technical decision may struggle to develop independent expertise.
For African pharmaceutical manufacturing, successful partnerships should strengthen the skills and systems available within African companies.
Quality Standards Will Determine Market Confidence
Medicines are not ordinary consumer products.
Inconsistent quality can create serious health risks.
Manufacturers must therefore meet applicable regulatory standards and maintain appropriate production controls.
These include manufacturing procedures, product testing, documentation, storage requirements and systems for identifying quality problems.
The World Health Organization’s prequalification programme is one mechanism used to assess certain health products against international quality, safety and efficacy requirements.
Meeting relevant standards can also influence whether manufacturers qualify for procurement by major health organisations.
For African pharmaceutical companies, quality assurance is not simply a compliance expense.
It is fundamental to patient safety, market access and commercial credibility.
Regional Procurement Can Support African Pharmaceutical Manufacturing
One of the challenges facing local manufacturers is uncertain demand.
A company may invest in production capacity without knowing whether buyers will consistently purchase its products.
Africa CDC and African leaders have identified pooled procurement as one way to address this problem.
The African Pooled Procurement Mechanism is intended to help aggregate demand and strengthen market opportunities for quality-assured health products manufactured on the continent.
In February 2026, African leaders reaffirmed their support for the mechanism as part of a broader strategy to develop local manufacturing.
Predictable purchasing arrangements can help manufacturers plan production and investment.
However, procurement commitments must be supported by financing, transparent processes and appropriate quality requirements.
Local production should not become an excuse for accepting products that fail to meet necessary standards.
African Pharmaceutical Companies Can Build Around Essential Medicines
The pharmaceutical industry includes a wide range of products.
Some medicines require complex manufacturing technologies and specialised facilities.
Others may be more suitable for established generic manufacturing processes.
Africa CDC’s 2025 annual report identified a substantial base of manufacturers producing essential medicines, including antibiotics, antimalarials, antiretrovirals, analgesics and medicines for hypertension.
It also reported emerging capacity in more complex products such as insulin, injectables and biological medicines.
These differences matter when companies consider investment.
African pharmaceutical companies should assess which product categories match their technical capabilities, capital resources and market opportunities.
Commercial success is more likely when manufacturers build around clearly defined areas of expertise.
Research and Development Must Become Part of the Industry
Manufacturing existing products is important.
Developing new products and improving production technologies can create additional value.
Africa’s pharmaceutical sector needs stronger connections between manufacturers, universities, research institutions and healthcare providers.
Research partnerships can help identify unmet medical needs, improve formulations and develop specialised manufacturing knowledge.
They can also create opportunities for African scientists and technical professionals.
However, pharmaceutical research requires rigorous testing, ethical oversight and appropriate regulatory approval.
Innovation should not be confused with making unsupported claims about medical effectiveness.
The long-term competitiveness of African pharmaceutical manufacturing will depend partly on the industry’s ability to develop knowledge, not only operate production facilities.
Pharmaceutical Manufacturing Can Create Skilled Employment
The sector requires professionals across multiple disciplines.
Pharmacists, chemists, microbiologists, engineers, laboratory specialists, production technicians and quality-assurance professionals all contribute to pharmaceutical operations.
Manufacturing expansion can also create demand for packaging, maintenance, logistics and specialised business services.
Africa CDC’s 2025 manufacturing assessment identified more than 570 pharmaceutical manufacturers across the continent, demonstrating that a production base already exists.
The challenge is strengthening that base and expanding its capabilities.
For African pharmaceutical companies, investment in workforce training should accompany investment in equipment.
A modern facility cannot operate effectively without people who understand the technical requirements of pharmaceutical production.
Smaller Businesses Can Participate in the Pharmaceutical Value Chain
Not every business opportunity requires establishing a medicine manufacturing plant.
The wider pharmaceutical industry depends on suppliers and service providers.
Companies can develop specialised packaging services, laboratory equipment support, compliant warehousing, temperature-controlled transportation, maintenance and digital inventory systems.
These activities can create opportunities for smaller enterprises with relevant expertise.
However, companies entering pharmaceutical supply chains must understand the standards applicable to their services.
A logistics provider handling temperature-sensitive medicines, for example, may need systems that differ substantially from those used for ordinary consumer products.
The growth of African pharmaceutical manufacturing can therefore support other industries when manufacturers develop reliable local supplier networks.
Regulatory Cooperation Can Support Regional Expansion
Africa’s pharmaceutical market is divided across countries with different regulatory systems.
Manufacturers seeking to sell products in several markets may face separate approval processes and documentation requirements.
This can increase costs and delay market entry.
The African Medicines Agency and wider regulatory harmonisation efforts are intended to strengthen cooperation across national regulatory authorities.
The objective is to support more consistent standards and improve access to quality-assured medical products.
For African pharmaceutical companies, stronger regulatory cooperation could make regional expansion more practical over time.
However, businesses must continue complying with the specific requirements that apply in each market.
Regional initiatives do not automatically replace national authorisation procedures.
Investment Must Reach the Right Parts of the Value Chain
Building pharmaceutical manufacturing capacity requires long-term capital.
Investors need to consider equipment costs, production technology, quality systems, research, working capital and market demand.
Some investments may be more effective when directed towards upgrading existing manufacturers.
Others may support new facilities, ingredient production or specialised services.
The International Finance Corporation has highlighted opportunities for private investment in African pharmaceutical manufacturing, including projects intended to improve access to essential medicines.
The commercial challenge is identifying investments that can become financially sustainable.
African pharmaceutical manufacturing will benefit most from capital that strengthens real production capability and responds to verified market needs.
Crest Africa and the Businesses Building Africa’s Health Economy
Africa’s industrial development story includes more than technology, energy and consumer products.
Healthcare manufacturing is also an important economic sector.
Crest Africa continues documenting the entrepreneurs, executives and companies contributing to Africa’s development.
The continent’s pharmaceutical ambitions create opportunities for manufacturers, researchers, investors and specialised service providers.
For African pharmaceutical companies, the opportunity is to develop businesses that combine commercial performance with products essential to public health.
The challenge is maintaining the standards and operational discipline required in such a sensitive industry.
Building Visibility Around Africa’s Pharmaceutical Innovators
Pharmaceutical manufacturing is a sector where credibility matters.
Empire Magazine Africa highlights entrepreneurs, executives and organisations contributing to business development across the continent.
Talented Women Network strengthens opportunities and visibility for women founders, executives and professionals, including those working in healthcare, research, science and manufacturing.
Laerryblue Media supports organisations and business leaders through strategic communication, media relations, reputation management and thought leadership.
For pharmaceutical companies, communication should remain accurate, evidence-based and consistent with applicable rules governing health-product promotion.
Reputation cannot replace regulatory approval or product quality.
It can help credible organisations communicate verified achievements and build stronger relationships with stakeholders.
What This Means For Africa
Africa’s pharmaceutical manufacturing ambitions represent an opportunity to connect industrial development with healthcare security.
The continent currently imports a substantial share of its medicines.
It also depends heavily on imported active pharmaceutical ingredients.
At the same time, Africa already has hundreds of pharmaceutical manufacturers and a growing policy framework intended to support local production.
The African Union’s 2040 ambition provides a long-term direction.
However, the target should not be mistaken for an achievement already secured.
Reaching it will require investment, technical expertise, stronger regulatory systems, predictable procurement and commercially sustainable manufacturers.
For African pharmaceutical companies, the opportunity is to build businesses capable of meeting these requirements.
For governments, the challenge is creating conditions that support investment while protecting patient safety and maintaining competitive markets.
Final Perspective
Africa cannot build a stronger pharmaceutical industry through policy declarations alone.
Factories must produce medicines that meet the required standards.
Manufacturers need reliable access to ingredients.
Researchers need opportunities to develop and apply knowledge.
Regulators need the capacity to evaluate products effectively.
Buyers need confidence in locally manufactured medicines.
And investors need evidence that production can remain commercially viable.
The continent’s ambition to meet at least 60% of its health product needs through local manufacturing by 2040 is significant.
But the real measure of progress will be the availability of safe, effective, quality-assured and affordable products.
For African pharmaceutical companies, this is an opportunity to build businesses whose value extends beyond financial returns.
For African pharmaceutical manufacturing, the next phase must focus on turning industrial ambition into dependable production.
Africa’s pharmaceutical future will be shaped by the companies and institutions capable of making that transition.
For more insight into the entrepreneurs, industries and innovations transforming the continent, visit Crest Africa and explore the stories shaping Africa’s economic future.
Don’t Miss This:
Image Credit: Magnific
